Professor John French attends Riverina Cardiology on a part time basis.

Professor French trained in molecular medicine and oxygen radical biochemistry in Christchurch, Adelaide and London (where he undertook a Wellcome Trust funded post doc in Molecular Medicine). His clinical training was largely in Auckland (NZ), where he was consultant cardiologist at Green Lane Hospital from 1992-2003, though he continued molecular genetic research in hypertrophic cardiomyopathy, and established a genetic cardiology clinic.

However, for the last 30+ years John has predominantly been a clinical trialist and outcomes researcher. A significant career highlight was the paper publication on emergency informed consent in ST-elevation myocardial infarction in the Lancet in 2003 showing that while consent processes may meet regulatory requirements, patient comprehension and competence to consent was not optimal. He presented at cardiovascular grand rounds at the Mayo Clinic, Rochester Minnesota. He has co-authored ~268 peer-reviewed papers.

Since January 2004 John French, an interventional cardiologist, has been Director of Cardiac Research at Liverpool Hospital NSW, though, with the clinical geneticists, setup a multidisciplinary monthly cardiac genetics clinic in 2006. John French’s current clinical research interests include cardiac biomarkers particularly high sensitivity troponins, treatments of ST-elevation myocardial infarction (he was National Leader of the STREAM-2 Trial [reported ACC 2023], and was a co-author of the 2016 Australian ACS guidelines (lead STEMI section). He chaired the clinical endpoints committees (CEC) of HERO-1, HERO-2 RAPID T, and PARTY trials and served on the CECs of PLATO, APEX-AMI and CANVAS trials. John French was PI of the rescue PCI (RAFT) trial. He has recently been national leader of the STREAM-2 and OYSSEY trials.